Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter . Of course, this means that it is time to reheat the coffee kettle for another cup of stimulation. …AstraZeneca said it will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, as U.K. Prime Minister Keir Starmer visited Beijing, Reuters writes. AstraZeneca has invested billions of dollars in the country since 2012, including $2.5 billion in a Beijing research and development hub in March last year, its second after a Shanghai site opened in 2024.